Logo

American Heart Association

  20
  0


Final ID: 4357419

Multidomain Risk Profiles and Disease Progression Across Atherosclerotic Vascular Beds

Abstract Body (Do not enter title and authors here): Background: Atherosclerotic cardiovascular disease (ASCVD) manifests variably across coronary (CAD), cerebrovascular (CVD), and peripheral artery (PAD) beds. The contributions of sociodemographic, clinical, lifestyle, and genetic domains to ASCVD onset, localization, and progression remain incompletely understood.

Objectives: To (1) evaluate how multidomain risk factors relate to ASCVD onset by vascular bed; (2) identify predictors associated with ASCVD localization; and (3) determine key drivers of progression from single- to multibed ASCVD.

Methods: We analyzed 468,266 UK Biobank participants without baseline ASCVD. Risk factor importance was assessed using multivariable Cox models and machine learning–derived SHapley Additive Explanations (SHAP). Age-varying hazard ratios were estimated. Multinomial logistic regression evaluated disease localization, and discrete-time multistate models examined transitions to single-bed, multibed, and fatal states. Analyses used ten multiple imputed datasets.

Results: Risk factor architecture varied by vascular bed (Fig. 1). PAD onset was dominated by inflammation and metabolic dysfunction—particularly C-reactive protein (CRP), HbA1c, and smoking (e.g., CRP hazard ratio [HR] 1.22, 95% CI 1.19–1.26)—while CAD was more strongly linked to low-density lipoprotein cholesterol (LDL-C; HR 1.23, 95% CI 1.21–1.25), the CAD polygenic risk score (PRS), and systolic blood pressure (SBP). CVD shared features with both PAD and CAD, with contributions from CRP, SBP, and socioeconomic deprivation. Healthy sleep and physical activity were protective. SHAP analyses confirmed these vascular bed–specific profiles. Age-varying models showed stronger effects of PRSs and clinical predictors before age 60. In multinomial models (Fig. 2), non-CAD phenotypes were more associated with CRP, HbA1c, and smoking, whereas CAD was more predicted by LDL-C and CAD PRS. Smoking showed the largest differential effect (odds ratio [OR] PAD vs CAD 2.09, 95% CI 1.93–2.26). Multistate models (Fig. 3) showed CRP, HbA1c, SBP, and CAD PRS predicted progression to multibed ASCVD, while transitions to death were driven by metabolic, renal, and inflammatory markers.

Conclusions: ASCVD risk factors differ in relative importance across vascular beds and stages. These findings underscore the need for vascular bed–specific prevention strategies that integrate early genetic risk stratification with aggressive management of modifiable factors across the disease continuum.
  • Supriami, Kelvin  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Flores, Alyssa Monica  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Urbut, Sarah  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Aragam, Krishna  ( Massachusetts General Hospital , Cambridge , Massachusetts , United States )
  • Natarajan, Pradeep  ( Massachusetts General Hospital , Brookline , Massachusetts , United States )
  • Ellinor, Patrick  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Fahed, Akl  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Author Disclosures:
    Kelvin Supriami: DO NOT have relevant financial relationships | Alyssa Monica Flores: DO NOT have relevant financial relationships | Sarah Urbut: DO NOT have relevant financial relationships | Krishna Aragam: No Answer | Pradeep Natarajan: DO have relevant financial relationships ; Researcher:Amgen, Genentech / Roche:Active (exists now) ; Other (please indicate in the box next to the company name):Vertex Pharmaceuticals (spousal employment):Active (exists now) ; Ownership Interest:Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, TenSixteen Bio:Active (exists now) ; Consultant:Allelica, CRISPR Therapeutics, Genentech/Roche, HeartFlow, Magnet Biomedicine:Past (completed) ; Consultant:AstraZeneca, Blackstone Life Sciences, Bristol Myers Squibb, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, GV, Merck, Novartis, Novo Nordisk, TenSixteen Bio, Tourmaline Bio:Active (exists now) ; Researcher:Allelica, Novartis:Past (completed) | Patrick Ellinor: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bayer AG:Active (exists now) ; Consultant:Bayer AG:Past (completed) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):BMS:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) | Akl Fahed: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:
More abstracts on this topic:
A Mixed Methods Analysis of Patient Knowledge in Peripheral Artery Disease

Reilly Margaret, Alagna Megan, Iroz Cassandra, Ho Emily, Hoel Andrew, Vavra Ashley, Lundberg Alexander, Ho Karen

A KLF2-BMPER-Smad1/5 checkpoint regulates high fluid shear stress-mediated artery remodeling

Deng Hanqiang, Zhang Jiasheng, Schwartz Martin

More abstracts from these authors:
Interactions Between Polygenic Risk Scores and Social Determinants of Health in Coronary Artery Disease: Insights from the UK Biobank

Sadek Carl, Lambermont Jul, Supriami Kelvin, Natarajan Pradeep, Fahed Akl

Identification of functional proteins in peripheral artery disease using proteogenomic analysis of European and African populations

Flores Alyssa Monica, Schuermans Art, Tian Haodong, Nakao Tetsushi, Koyama Satoshi, Urbut Sarah, Yu Zhi, Natarajan Pradeep

You have to be authorized to contact abstract author. Please, Login
Not Available